AXSOME THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
AXSOME THERAPEUTICS, INC. (AXSM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $0 for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2016-11-14
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2016-09-30 was $0.00.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2016-06-30 was $0.00.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2016-03-31 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $0.00 10-Q/A · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |